Sisli Florence Nightingale Hospital, Istanbul, Turkey.
Hepatobiliary Pancreat Dis Int. 2012 Jun;11(3):256-61. doi: 10.1016/s1499-3872(12)60157-x.
In liver transplantation or resection for hepatocellular carcinoma (HCC), patient selection depends on morphological features. In patients with HCC, we performed a clinicopathological analysis of risk factors that affected survival after liver transplantation.
In 389 liver transplantations performed from 2004 to 2010, 102 were for HCC patients. Data were collected retrospectively from the Organ Transplantation Center Database. Variables were as follows: age, gender, preoperative alpha-fetoprotein (AFP) levels, Child-Pugh and MELD scores, prognostic staging criteria (Milan and UCSF), etiology, number of tumors, the largest tumor size, total tumor size, multifocality, intrahepatic portal vein tumor thrombosis, bilobarity, and histological differentiation.
One hundred and two patients were evaluated. The 5-year overall survival rate was 56.5%. According to the UCSF criteria, 63% of the patients were within and 37% were beyond UCSF (P=0.03). Ten patients were excluded (one with fibrolamellary HCC and 9 because of early postoperative death without HCC recurrence), and 92 patients were assessed. The mean age of the patients was 56.5+/-6.9 years. Sixty-two patients underwent living donor liver transplantations. The mean follow-up time was 29.4+/-22.6 months. Fifteen patients (16.3%) died in the follow-up period due to HCC recurrence. Univariate analysis showed that AFP level, intrahepatic portal vein tumor thrombosis, histologic differentiation and UCSF criteria were significant factors related to survival and tumor recurrence.The 5-year estimated overall survival rate was 62.2% in all patients. According to the UCSF criteria, and the 5-year overall survival rate was 66.7% within and 52.7% beyond the criteria (P=0.04). Multivariate analysis showed that AFP level and poor differentiation were independent factors.
For proper patient selection in liver transplantation for HCC, prognostic criteria related to tumor biology (especially AFP level and histological differentiation) should be considered. Poor differentiation and higher AFP levels are indicators of poor prognosis after liver transplantation.
在肝移植或肝癌切除术(HCC)中,患者选择取决于形态学特征。在 HCC 患者中,我们对影响肝移植后生存的危险因素进行了临床病理分析。
在 2004 年至 2010 年期间进行的 389 例肝移植中,有 102 例为 HCC 患者。数据从器官移植中心数据库中回顾性收集。变量如下:年龄、性别、术前甲胎蛋白(AFP)水平、Child-Pugh 和 MELD 评分、预后分期标准(米兰和 UCSF)、病因、肿瘤数量、最大肿瘤大小、总肿瘤大小、多发性、肝内门静脉肿瘤血栓形成、双侧性和组织学分化。
对 102 例患者进行了评估。5 年总生存率为 56.5%。根据 UCSF 标准,63%的患者在 UCSF 内,37%的患者在 UCSF 外(P=0.03)。10 例患者被排除(1 例为纤维板层 HCC,9 例因术后早期死亡且无 HCC 复发),92 例患者被评估。患者的平均年龄为 56.5+/-6.9 岁。62 例患者接受活体供肝移植。平均随访时间为 29.4+/-22.6 个月。在随访期间,有 15 例(16.3%)患者因 HCC 复发而死亡。单因素分析显示,AFP 水平、肝内门静脉肿瘤血栓形成、组织学分化和 UCSF 标准是与生存和肿瘤复发相关的显著因素。所有患者的 5 年估计总生存率为 62.2%。根据 UCSF 标准,5 年总生存率在标准内为 66.7%,在标准外为 52.7%(P=0.04)。多因素分析显示,AFP 水平和低分化是独立因素。
为了在 HCC 肝移植中进行适当的患者选择,应考虑与肿瘤生物学相关的预后标准(特别是 AFP 水平和组织学分化)。低分化和高 AFP 水平是肝移植后预后不良的指标。